UK National Guideline for the management of Donovanosis 2017

Clinical Effectiveness Group (CEG), British Association of Sexual Health and HIV (BASHH)

Nigel O’Farrell, London North West Healthcare NHS Trust, Pasteur Suite, Ealing Hospital, London UB13HW

Anwar Hoosen, Medical Microbiology, University of Free State, Bloemfontein, South Africa

Margaret Kingston, Consultant Genitourinary Medicine, The Northern Sexual Health, Contraception and HIV Service, The Hathersage Centre, 280 Upper Brook Street, Manchester M13 0FH (BASHH CEG Editor)

Introduction:
The objective of this guideline is to provide guidance for the diagnosis and management of Donovanosis, a now rare sexually transmitted infection. This guidance is primarily for professionals working in UK Sexual Health services (although others may find it useful) and refers to the management of individuals presenting with possible symptoms of Donovanosis who are over the age of 16.

An updated literature review since the last CEG guideline produced for this condition in 2011 has shown few new developments. Most reports in the literature relate to cases of unusual presentations of the condition.

Methods:
Search strategy: A Medline search using the terms donovanosis and granuloma inguinale between 1950 and 2016 was undertaken. Due to the rarity of the condition in the UK piloting of the guideline was not considered possible and we were not able to locate a patient to provide input or generate interest from patient representatives to review the guideline.

Aetiology
There is still debate about the correct nomenclature of the causative organism. The cause was originally identified as Calymmatobacterium granulomatis. However based on evidence of phylogenetic similarity with Klebsiella species, a proposal was put forward that the organism be reclassified as Klebsiella granulomatis comb nov [1]. However similarities of only 95% to Klebsiella were identified in another study [2].

Transmission
There has been debate about whether donovanosis is always sexually transmitted. The majority of cases are in the 20-40 age group; the most sexually active. Amongst sexual partners of index cases, wide variations in the rates of infection have been reported ranging from 1-2 % in Papua New Guinea [3] and the USA [4] to 50% of marital partners in India [5, 6].

Epidemiology
Donovanosis is now a rare infection and appears to be dying out. The main foci in recent times have been in Papua New Guinea, southern Africa, parts of India and Brazil. An eradication programme in Australia has led to its virtual elimination there [7].
As a cause of genital ulceration that bleeds readily, the risk of associated HIV infection is increased and HIV testing should be recommended for all cases [8].

Clinical features

The first sign of infection is usually a firm papule or subcutaneous nodule that later ulcerates. Four types of donovanosis are described classically [9]:

1) Ulcerogranulomatous is the most common variant; non tender, fleshy, exuberant, single or multiple, beefy red ulcers that bleed readily when touched.

2) Hypertrophic or verrucous type, an ulcer or growth with a raised irregular edge, sometimes with a walnut appearance.

3) Necrotic, usually a deep foul smelling ulcer causing tissue destruction.

4) Sclerotic with extensive fibrous and scar tissue.

The genitals are affected in 90% of cases and the inguinal area in 10%. Extranetal cases occur in 6% of cases- sites include the lip, gums, cheek, palate, and pharynx. Atypical cases are reported in children usually affecting the facial region [10]. Lymphadenitis is uncommon. Dissemination is rare; secondary spread to liver and bone may occur and is usually associated with pregnancy and cervical lesions.

The usual sites of infection are in men, the prepuce, coronal sulcus, frenum and glans penis and in women, the labia minora, and fourchette. Lesions tend to grow more rapidly during pregnancy.

Squamous cell carcinoma of the penis may both mimic and complicate donovanosis and a biopsy should be done if antibiotics fail to effect resolution of ulcers [11].

Laboratory diagnosis

Direct microscopy: This is the quickest and most reliable method. A rapid Giemsa can be used to stain tissue smears that should be prepared by rolling a swab firmly across the ulcer and rolling this swab evenly across a glass slide to deposit ulcer material [12]. Characteristically there are large mononuclear cells with intracytoplasmic cysts filled with deeply stained Gram negative Donovan bodies. These bodies are pleomorphic and sized 1-2 x 0.5- 0.7µm. Depending on the stain used bipolar densities and a capsule may be visible.

Histologic examination for Donovan bodies is best done using Giemsa or Silver stains. The characteristic picture show chronic inflammation with infiltration of plasma cells and
polymorphonuclear leucocytes. Polymerase chain reaction (PCR) methods include a
colorimetric detection method [13, 14] and a genital ulcer multiple PCR test using an in
house nucleic acid amplification technique with *C. granulomatis* primers [15]. However, there
are no commercial PCR tests for donovanosis currently available. Culture has only been
accomplished in two laboratories in recent times and is not available routinely [16, 17].
Serology has been used in the past but is not reliable or routinely available.

**Management**

Samples for analysis should ideally be taken before treatment is given but antibiotics should
not be delayed whilst waiting for results. Patients should be reassured that donovanosis is a
treatable condition that will be cured if the correct antibiotic course is completed. A fact sheet
for patients has been produced by the New South Wales Communicable Diseases section,
Routine screening for other sexually transmitted infections is required.

**Recommended regimens:** all regimens are for 3 weeks or until lesions have completely
healed:

1. Azithromycin 1 g weekly or 500mg daily orally: 1B [18].

**Alternative regimens:**

2. Doxycycline 100mg bd orally: 1C (Evidence is not available from clinical trials but
   older tetracyclines have been observed to be effective) [20]
3. Erythromycin 500mg 4 times daily orally. Recommended in pregnancy: 1C [21]
4. Gentamicin 1 mg/kg every 8 hours parenterally can also be used as an adjunct if
   lesions are slow to respond 1C [22]

**Treatment in pregnancy:**

1. Erythromycin 500mg qds orally is recommended in pregnancy: 1C. Azithromycin could
   also be used: 1g weekly 1D

**Treatment of children:**

1. Azithromycin 20mg/kg orally once daily: 1C
Prophylactic antibiotics should be considered in neonates born to mothers with genital lesions; the recommended regimen is azithromycin 20mg/kg once daily for 3 days 1C [23].

**Partner management**

In the absence of any reliable screening test and the long incubation period, all sexual contacts of cases in the last 6 months should be checked for possible lesions by clinical examination.

**Follow up**

Patients should be followed up until lesions have healed completely.

Auditable outcome measures: All cases should be subjected to clinicopathological review by an experienced microscopist.
References


viruses, *Haemophilus ducreyi*, *Treponema pallidum*, and *Calymmatobacterium (Klebsiella)*

*Calymmatobacterium granulomatis*: the aetiological agent of granuloma inguinale

17. Carter J, Hutton S, Sriprakash KS et al. Culture of the causative organism for
donovanosis (*Calymmatobacterium granulomatis*) in Hep-2 cells. J Clin Micro 1997; 35:
2915-7

18. Bowden FJ, Mein J, Plunkett C et al. Pilot study of azithromycin in the treatment of

Vener Dis 1980;56:412-3

20. Greenblatt RB, Barfield WE, Dienst RB et al. Terramycin in the treatment of granuloma


22. Bowden FJ et al. Donovonosis causing cervical lymphadenopathy in a five-month old